Achieve Life Sciences (ACHV)
NASDAQ:ACHV
Want to see ACHV full AI Analyst Report?
ACHV Stock Chart & Stats
$5.10
-$0.11(-3.08%)
At close: 4:00 PM EST
$5.10
-$0.11(-3.08%)
Day’s Range― - ―
52-Week Range$2.00 - $6.15
Previous CloseN/A
Volume131.37K
Average Volume (3M)1.27M
Market Cap
$516.38M
Enterprise Value$524.81M
Total Cash (Recent Filing)$29.27M
Total Debt (Recent Filing)$14.95M
Price to Earnings (P/E)―
Beta2.69
Next Earnings
Aug 06, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding102,659,060
10 Day Avg. Volume1,279,396
30 Day Avg. Volume1,267,696
Financial Highlights & Ratios
PEG Ratio-4.92
Price to Book (P/B)10.07
Price to Sales (P/S)0.00
P/FCF Ratio-4.38
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.16K
Enterprise Value/Ebitda-10.21
Forecast
1Y Price Target
$13.20Price Target Upside158.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase III EfficacyRobust, replicated Phase III efficacy—notably large absolute and odds-ratio benefits in a hard-to-treat subgroup—provides durable clinical differentiation. This underpins payer coverage potential, physician adoption, and a stronger commercial value proposition if regulatory approval is secured.
Transformational FinancingA sizeable private placement materially extends runway for resubmission, additional trials and commercial planning, reducing near-term dilution pressure and lowering default risk. Long-term, committed strategic investors also improve access to further capital and sector expertise for launch execution.
Intellectual PropertyLong-dated IP protection supports a durable franchise and pricing power post-approval. Extended exclusivity enhances long-term revenue potential, increases partner/licensing leverage, and justifies sustained commercial investments and field force deployment.
Bears Say
No Revenue & Heavy Cash BurnAs a pre-commercial biotech, persistent large net losses and negative operating/free cash flow mean continuous external financing is required. That dynamic increases dilution risk, constrains discretionary spend, and limits ability to absorb delays or scale commercial investments without additional funding.
Rising Leverage & Weakened EquityShrinking equity and higher leverage reduce financial flexibility and raise refinancing and covenant risks. Stable absolute debt against a smaller equity base elevates balance-sheet vulnerability to execution setbacks and heightens dependence on investor support for near- and medium-term operations.
Expected FDA CRL & Manufacturing Resubmission RiskAn anticipated CRL and required resubmission create structural regulatory and execution risk: tech transfer to a new U.S. manufacturer, unknown resubmission class and timeline, and potential delays to launch. These risks materially affect timing of revenue generation and commercial momentum.
Achieve Life Sciences News
ACHV FAQ
What was Achieve Life Sciences’s price range in the past 12 months?
Achieve Life Sciences lowest stock price was $2.00 and its highest was $6.15 in the past 12 months.
What is Achieve Life Sciences’s market cap?
Achieve Life Sciences’s market cap is $516.38M.
When is Achieve Life Sciences’s upcoming earnings report date?
Achieve Life Sciences’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were Achieve Life Sciences’s earnings last quarter?
Achieve Life Sciences released its earnings results on May 12, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.299 by $0.109.
Is Achieve Life Sciences overvalued?
According to Wall Street analysts Achieve Life Sciences’s price is currently Undervalued.
Does Achieve Life Sciences pay dividends?
Achieve Life Sciences does not currently pay dividends.
What is Achieve Life Sciences’s EPS estimate?
Achieve Life Sciences’s EPS estimate is -0.16.
How many shares outstanding does Achieve Life Sciences have?
Achieve Life Sciences has 102,659,060 shares outstanding.
What happened to Achieve Life Sciences’s price movement after its last earnings report?
Achieve Life Sciences reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.299. Following the earnings report the stock price went up 7.156%.
Which hedge fund is a major shareholder of Achieve Life Sciences?
Currently, no hedge funds are holding shares in ACHV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Achieve Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.20 (158.82% Upside)
$13.20 (158.82% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 42.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.86%
12-Months-Change
Fundamentals
Return on Equity
-193.49%
Trailing 12-Months
Asset Growth
21.01%
Trailing 12-Months
Company Description
Achieve Life Sciences
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
ACHV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: a substantial financing, experienced new leadership and commercial hires, U.S. manufacturing partnership with initial batches, robust Phase III efficacy (notably 32.4% vs 6% in hard-to-treat patients) and supportive mechanistic/tolerability data. The principal negatives are an anticipated FDA CRL tied to a third-party manufacturer OAI, requiring an NDA resubmission in Q4 2026 and introducing execution risk around the manufacturing tech transfer to Adare and timing uncertainty. Overall, the company appears well capitalized and operationally proactive to address the delays and pursue a planned H1 2027 launch, but near-term regulatory and manufacturing execution risks remain.View all ACHV earnings summariesACHV Stock 12 Month Forecast
Average Price Target
$13.20
▲(158.82% Upside)
Technical Analysis
Ownership Overview
0.87% Insiders
4.23% Mutual Funds
7.02% Other Institutional Investors
84.20% Public Companies and
Individual Investors